• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Influenza Virus Vaccine for the 2013-2014 Season

Cumulative 2013/2014 Season Lot Release Status (Updated 3/12/2014)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.

ManufacturerTotal Number of Lots Released by FDA
AFLURIA
CSL Limited
38
Fluarix
GlaxoSmithKline Biologicals
8
Fluarix - Quadrivalent
GlaxoSmithKline Biologicals
13
Flublok
Protein Sciences Corporation
6
Flucelvax
Novartis Vaccines and Diagnostics, Inc.
7
FluLaval
ID Biomedical Corp. of Quebec
19
FluLaval Quadrivalent
ID Biomedical Corp.
3
FluMist Quadrivalent
MedImmune, LLC
41
Fluvirin
Novartis Vaccines and Diagnostics Limited
41
Fluzone
Sanofi Pasteur, Inc.
70
Fluzone Quadrivalent
Sanofi Pasteur, Inc.
17

FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Rockville, Maryland, on February 27, 2013, to select the influenza viruses for the composition of the influenza vaccine for the 2013-2014 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2012-2013 vaccines, and the availability of candidate strains and reagents.|

The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2013-2014 influenza season contain the following:

  • an A/California/7/2009 (H1N1)-like virus;
  • an (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011;
  • a B/Massachusetts/2/2012-like virus.

The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:

  • a B/Brisbane/60/2008-like virus